Innate Pharma SA (IPHA) - Dilution Analysis

Visualizing historical and potential share dilution over time

View Stock Details

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Dilution Analysis

Medium Risk

Moderate dilution risk

Last updated: April 01, 2026

Risk Assessment Details

Potential Dilution: 0.0% of current shares

Recent Dilution: 11.8% (2 years)

Historical Dilution Factor: moderate recent dilution

Outstanding Shares

94M

Potential Supply

Additional shares possible

Splits

None

Past 2 years

Summary

IPHA currently has 93.7M outstanding shares. with minimal authorized share overhang for future dilution. The company has diluted shareholders by 11.8% over the past 2 years through share issuances.

Share Structure Timeline

Outstanding Shares

Total Supply

Historical Data Points

Date	Event	Outstanding
Apr 01, 2026	20-F filing \| 93.7M shares outstanding	94M
Apr 30, 2025	20-F filing \| 83.8M shares outstanding	84M
Apr 04, 2024	20-F filing \| 80.5M shares outstanding	80M
Dec 20, 2023	F-3 filing: The filing is an F-3 form, indicating a shelf registration for the offering of ordinary shares, including ADSs, up to an aggregate amount of $200,000,000.	80M
Apr 06, 2023	20-F filing \| 79.5M shares outstanding	80M
Apr 04, 2022	20-F filing \| 79.5M shares outstanding	80M
Apr 27, 2021	20-F filing \| 79.0M shares outstanding	79M
Jan 13, 2021	F-3 filing: The filing registers an indeterminate number of ordinary shares for sale by the registrant from time to time, with a maximum aggregate offering price not to exceed $200,000,000, including ordinary shares represented by American Depositary Shares (ADSs).	79M
Apr 24, 2020	20-F filing \| 78.6M shares outstanding	79M

Back to IPHA Details